The Austin-based startup will test its high-bandwidth device to help restore speech in people with extremely limited movement.
GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid.
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of editing human embryos to make disease-free children.
With the demand for human donor organs desperately outstripping supply, scientists are working to see if genetically edited pig organs can bridge the gap.
Another round of terminations, combined with previous layoffs and departures, has reduced the Centers for Disease Control and Prevention workforce by about 3,000 people since January.
The CDC no longer broadly recommends the Covid-19 vaccine, but US residents will still be able to get one if they want.
California-based Cognixion is launching a clinical trial to allow paralyzed patients with speech disorders the ability to communicate without an invasive brain implant.
The embryos weren’t used to try to establish a pregnancy, but the researchers behind the technique say it could one day be used to address infertility.
Mindstate Design Labs, backed by Silicon Valley power players, has created what its CEO calls “the least psychedelic psychedelic that’s psychoactive.”